https://www.targetedonc.com/view/fda-approves-sevabertinib-in-her2-mutated-nonsquamous-nsclc
FDA Approves Sevabertinib in HER2-Mutated Nonsquamous NSCLC | Targeted Oncology - Immunotherapy,...
Oct 12, 2026 - The FDA has approved sevabertinib for HER2-mutant nonsquamous non–small cell lung cancer.
fdaapprovessevabertinibmutatednonsquamous